Professional Documents
Culture Documents
References
1. Ribera Montes C, Pascual Perez R, Perez Barba
C, Orozco Beltran D, Pedrera Carbonell V. Risk
factors for asymptomatic bacteriuria in women
with diabetes [letter]. Clin Infect Dis 2004; 39:
17323 (in this issue).
2. Bonadio M, Boldrini E, Forotti G, et al. Asymptomatic bacteriuria in women with diabetes:
influence of metabolic control. Clin Infect Dis
2004; 38:e415.
3. Geerlings SE, Stolk RP, Camps MJ, et al.
Asymptomatic bacteriuria may be considered a
complication in women with diabetes. Diabetes
4.
5.
6.
7.
8.
Acknowledgments
Potential conflicts of interest. V.L.Y. has received research funding from Abbott, Pfizer, and
Ortho-McNeil. All other authors: no conflicts.
Victor L. Yu,1 Julio Ramirez,2 Jorge Roig,3
and Miguel Sabria4
11.
12.
13.
14.
References
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25. Mulazimoglu L, Yu VL. Can legionnaires disease be diagnosed by clinical criteria? A critical
review. Chest 2001; 120:1049953.
26. Yu VL, Greenberg RN, Zadeikis N, et al. Levofloxacin efficacy in the treatment of community-acquired legionellosis. Chest 2004;
125:21359.
27. Squier C, Lin YE, Stout JE. Waterborne pathogens: Legionella and other opportunistic
pathogens. In: Hibbard CE, Klingelsmith WD,
Sunseri AJ, eds. Healthcare Facilities Management Series. Document 055995. Chicago, IL:
American Society for Healthcare Engineers of
the American Hospital Association, 2001.
28. Garcia-Fulgueiras A, Navarro C, Fenoll C, et
al. legionnaires disease outbreak in Murcia,
Spain. Emerg Infect Dis 2003; 9:915.
29. Muder RR, Yu VL. Infection due to Legionella
species other than L. pneumophilla. Clin Infect
Dis 2002; 35:9908.
30. Plouffe JF, Breiman RF, Fields BS, et al. Azithromycin in the treatment of Legionella pneumonia requiring hospitalization. Clin Infect
Dis 2003; 37:147580.
31. Genne D, Siegrist HH, Humair L, Janin-Jaquat
B, de Torrente A. Clarithromycin versus
amoxicillin-clavulanate in the treatment of
community-acquired pneumonia. Eur J Clin
Microbiol Infect Dis 1997; 16:7838.
32. Liippo K, Tala E, Puolijoki H, Bruckner OJ,
Rodrig J, Smits JPH. A comparative study of
dirithromycin and erythromycin in bacterial
pneumonia. J Infect 1994; 28:1319.
33. Valtonen M, Cars O, Wahl M, Saikku P, Jean
C. Oral empiric treatment of communityacquired pneumonia: a multicenter, doubleblind, randomized study comparing sparfloxacin with roxithromycin. Chest 1996; 110:
1499506.
34. Dunbar LM, Khashab MM, Kahn JB, Zadeikis
N, Xiang JX, Tennenberg AM. Efficacy of 750mg, 5-day levofloxacin in the treatment of
community-acquired pneumonia caused by
atypical pahtogens. Curr Med Res Opin
2004; 20:55563 (erratum: Curr Med Res
Opin 2004; 20:967).
35. Moutan Y, Leroy O, Beuscart C, et al. Efficacy
of intravenous ofloxacin: a French multicentre
trial in 185 patients. J Antimicrob Chemother
1990; 26(Suppl D):11521.
36. Gentry LO, Lipsky B, Farber MO, Tucker B,
Rodriguez-Gomez C. Oral ofloxacin therapy
for lower respiratory tract infection. South
Med J 1992; 85:148.
37. Donowitz GR, Brandon ML, Salisburgy JP, et
al. Sparfloxacin versus cefaclor in the treatment of patients with community-acquired
pneumonia: a randomized, double-masked,
comparative, multicenter study. Clin Ther
1997; 19:93653.
38. Topkis S, Swarz H, Breisch SA, Maroli AN.
Efficacy and safetey of grepafloxacin 600 mg
daily for 10 days in patients with communityacquired pneumonia. Clin Ther 1997; 19:
97588.
39. Myburgh J, Nagel GJ, Petschel E. The efficacy
and tolerance of a three-day course of azith-
40.
41.
42.
43.
44.
Reply to Yu et al.
SirWe appreciate the opportunity to respond to the letter of Yu et al. [1], but we
were disappointed by its inflammatory
tone and by the fact that many of their
concerns resulted from incorrect interpretation or selective referencing of the Infectious Diseases Society of America
(IDSA) guidelines on management of
community-acquired pneumonia (CAP)
[2]. Their criticism of our recommendations for Legionella testing suggests that
Legionella species are the third or fourth
most common cause of CAP in immunocompetent hosts. This is clearly incorrect; their own article [3] deals with cases
of severe CAP, not all CAP cases.
They refer to the principle of emphasizing laboratory diagnosis to allow targeted antibiotic therapy. We in fact do exactly this. Recognizing the morbidity and
mortality associated with CAP among
hospitalized patients, we stressed initial
empiric therapy aimed at the pneumococcus and Legionella species, which are
the pathogens associated with the highest
Acknowledgments
Potential conflicts of interest. L.A.M. has received research funding from Bayer, Bristol-Myers
Squibb, and Pharmacia; is a consultant for Bayer,
Pfizer, Aventis, and Ortho-McNeil; and is a member of the speakers bureau for Pfizer, Aventis, Wyeth, Ortho-McNeil, and Bayer. J.G.B. is on the HIV
Advisory Board of Bristol-Myers Squibb. T.M.F.
has received research funding from Abbott,
AstraZeneca, Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, and Wyeth; is a consultant for
Aventis, Bayer, GlaxoSmithKline, Ortho-McNeil,
Pfizer, and Wyeth; and is a member of the speak-